What National Vision Holdings, Inc. told the SEC could break it.

National Vision has acute supplier concentration in its core product inputs. It has agreed to exclusively purchase almost all of its eyeglass lenses from a single supplier — approximately 86% of fiscal 2025 lens expenditures came from that one vendor — and approximately 96% of contact-lens expenditures were with just three vendors (frames are less concentrated, ~55% from two vendors). It also relies on a third-party vendor for contact-lens fulfillment/distribution, and substantially all inventory flows through a single distribution center in Lawrenceville, Georgia. A disruption, price action, quality issue, or contract dispute at the sole lens supplier, a key contact-lens vendor, or the single DC could materially impair its ability to fulfill orders. Suppliers are unnamed, so this registers as a high-severity sole-source/limited-supplier risk.

“we have agreed to exclusively purchase almost all of our eyeglass lenses from one supplier. During fiscal year 2025, approximately 86% of lens expenditures were from this vendor and approximately 96% of contact lens expenditures were with three vendors.”

An increasing share of National Vision's revenue flows through third-party managed-vision-care payors rather than direct cash-pay customers: managed care represented 42% of revenue from continuing operations in fiscal 2025 (with a stated path toward 50%). It depends on maintaining relationships with almost all U.S. vision-care insurers, including the major carriers that dominate market share, which subjects it to payor concentration risk — loss of, or adverse repricing/reimbursement-rate cuts by, a dominant carrier would significantly affect revenue. This exposure is compounded by healthcare-policy risk: changes to Medicaid or other reimbursement programs could reduce or eliminate coverage for insurance-funded eye exams or eyewear. The payors are not individually named, so this registers as a concentration risk.

“We maintain strong relationships with almost all vision care insurers in the U.S. including the major carriers who dominate market share, subjecting us to concentration risk.”

National Vision's supply chain straddles two tariff-sensitive jurisdictions: the majority of its eyeglass frames are sourced and manufactured in China, and its outsourced optical laboratories are located in Mexico. It states that tariffs have historically not been material (less than 10% of costs applicable to revenue are subject to Chinese-import tariffs) and that it has taken mitigation steps — including terminating its outsourced China laboratory relationship in early 2024 (tied to winding down its Walmart partnership) to reduce China tariff exposure — but warns that tariff rates fluctuate and that significant additional tariffs on Mexico or China imports, or a termination/material amendment of the USMCA (which is under joint review in 2026), could raise costs, delay shipments, and force it to find alternative merchandise and lab sources. A concrete, two-country trade-policy exposure on its product and lab supply chain.

“if the U.S. imposes significant additional tariffs or other restrictions on imports from Mexico, where our outsourced optical laboratories are located, or China, where the majority of our frames are sourced and manufactured”